Brainstorm cell therapeutics announces grant of a new brazilian patent covering methods of manufacturing nurown®

New york, feb. 15, 2022 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the brazilian patent office has granted the patent application titled: "a method of generating cells which secrete brain derived neurotrophic factor (bdnf), glial derived neurotrophic factor (gdnf), hepatocyte growth factor (hgf) and vascular endothelial growth factor (vegf), wherein said cells do not secrete nerve growth factor (ngf)." the granted claims cover a method of manufacturing msc-ntf cells (nurown®).
BCLI Ratings Summary
BCLI Quant Ranking